6 research outputs found
Survival of pancreatic cancer cells lacking KRAS function
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. Here we model complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate that KRAS is dispensable in a subset of human and mouse PDAC cells. Remarkably, nearly all KRAS deficient cells exhibit phosphoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression profiles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the suppression of metastasis-related genes. Collectively, these data underscore the potential for PDAC resistance to even the very best KRAS inhibitors and provide insights into mechanisms of response and resistance to KRAS inhibition
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
Although it has become increasingly clear that cancers display extensive cellular heterogeneity, the spatial growth dynamics of genetically distinct clones within developing solid tumours remain poorly understood. Here we leverage mosaic analysis with double markers (MADM) to trace subclonal populations retaining or lacking p53 within oncogenic Kras-initiated lung and pancreatic tumours. In both models, p53 constrains progression to advanced adenocarcinomas. Comparison of lineage-related p53 knockout and wild-type clones reveals a minor role of p53 in suppressing cell expansion in lung adenomas. In contrast, p53 loss promotes both the initiation and expansion of low-grade pancreatic intraepithelial neoplasia (PanINs), likely through differential expression of the p53 regulator p19ARF. Strikingly, lineage-related cells are often dispersed in lung adenomas and PanINs, contrasting with more contiguous growth of advanced subclones. Together, these results support cancer type-specific suppressive roles of p53 in early tumour progression and offer insights into clonal growth patterns during tumour development
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
© 2018 American Chemical Society. Human pancreatic ductal adenocarcinoma (PDAC) contains a distinctively dense stroma that limits the accessibility of anticancer drugs, contributing to its poor overall prognosis. Nanoparticles can enhance drug delivery and retention in pancreatic tumors and have been utilized clinically for their treatment. In preclinical studies, various mouse models differentially recapitulate the microenvironmental features of human PDAC. Here, we demonstrate that through utilization of different organic cosolvents and by doping of a homopolymer of poly(ϵ-caprolactone), a diblock copolymer composition of poly(ethylene oxide)-block-poly(ϵ-caprolactone) may be utilized to generate biodegradable and nanoscale micelles with different physical properties. Noninvasive optical imaging was employed to examine the pharmacology and biodistribution of these various nanoparticle formulations in both allografted and autochthonous mouse models of PDAC. In contrast to the results reported with transplanted tumors, spherical micelles as large as 300 nm in diameter were found to extravasate in the autochthonous model, reaching a distance of approximately 20 μm from the nearest tumor cell clusters. A lipophilic platinum(IV) prodrug of oxaliplatin was further able to achieve a ∼7-fold higher peak accumulation and a ∼50-fold increase in its retention half-life in pancreatic tumors when delivered with 100 nm long worm-like micelles as when compared to the free drug formulation of oxaliplatin. Through further engineering of nanoparticle properties, as well as by widespread adoption of the autochthonous tumor model for preclinical testing, future therapeutic formulations may further enhance the targeting and penetration of anticancer agents to improve survival outcomes in PDAC
Imaging glioma progression by intravital microscopy
We describe here a method for generating mouse orthotopic gliomas in order to follow their progression over time by multi-photon laser scanning microscopy. After craniotomy of the parietal bone, glioma cells are implanted in the brain cortex and a glass window is cemented atop, allowing chronical imaging of the tumor. The expression of different fluorescent proteins in tumor cells and in specific cell types of a number of currently available transgenic mouse strains allows obtaining multicolor 3D images of the tumor over time. This technique is suitable both to evaluate the effect of pharmacological treatments and to unravel basic mechanisms of tumor-host interactions
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
Human pancreatic ductal adenocarcinoma
(PDAC) contains a distinctively
dense stroma that limits the accessibility of anticancer drugs, contributing
to its poor overall prognosis. Nanoparticles can enhance drug delivery
and retention in pancreatic tumors and have been utilized clinically
for their treatment. In preclinical studies, various mouse models
differentially recapitulate the microenvironmental features of human
PDAC. Here, we demonstrate that through utilization of different organic
cosolvents and by doping of a homopolymer of polyÂ(ε-caprolactone),
a diblock copolymer composition of polyÂ(ethylene oxide)-<i>block</i>-polyÂ(ε-caprolactone) may be utilized to generate biodegradable
and nanoscale micelles with different physical properties. Noninvasive
optical imaging was employed to examine the pharmacology and biodistribution
of these various nanoparticle formulations in both allografted and
autochthonous mouse models of PDAC. In contrast to the results reported
with transplanted tumors, spherical micelles as large as 300 nm in
diameter were found to extravasate in the autochthonous model, reaching
a distance of approximately 20 μm from the nearest tumor cell
clusters. A lipophilic platinumÂ(IV) prodrug of oxaliplatin was further
able to achieve a ∼7-fold higher peak accumulation and a ∼50-fold
increase in its retention half-life in pancreatic tumors when delivered
with 100 nm long worm-like micelles as when compared to the free drug
formulation of oxaliplatin. Through further engineering of nanoparticle
properties, as well as by widespread adoption of the autochthonous
tumor model for preclinical testing, future therapeutic formulations
may further enhance the targeting and penetration of anticancer agents
to improve survival outcomes in PDAC
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
© 2020 Elsevier Inc. Obesity is an intrinsic driver of PDAC in mice, leading to a remodeling of beta cells to increase CCK secretion and playing a role early in pancreatic cancer development that can be intercepted by weight loss